Chardan Capital Maintains Buy on ProQR Therapeutics, Maintains $4 Price Target
Benzinga Newsdesk 12 months ago
NewsPrice TargetAnalyst Ratings
Chardan Capital analyst Keay Nakae maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and maintains $4 price target.
Chardan Capital analyst Keay Nakae maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and maintains $4 price target.